An Expanded Access Program for Elotuzumab in Combination with Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
|Effective start/end date||5/1/15 → 12/31/16|
- BRISTOL-MYERS SQUIBB COMPANY
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.